ClinicalTrials.gg
RecruitingNCT04018118COHESIONUpdated Feb 20, 2026

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes

An observational study in Eosinophilia and Hypereosinophilic Syndrome, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-02-20.

Primary conditionHypereosinophilic SyndromeRegistry: EosinophiliaReclassifiedWhy we changed it
Registry
Eosinophilia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypereosinophilic Syndrome
Why
  1. The study's listed conditions name Hypereosinophilic Syndrome, a narrower term within Eosinophilia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hypereosinophilic Syndrome with a site in France — 2 open to participants now, 3 under way, 2 of them phase 3. Hypereosinophilic Syndrome · France.

Started
2019
the only one that year
Observational
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
2 of 10
University Hospital, Lille

Among the 10 studies in Hypereosinophilic Syndrome with a site in France, this one is the only one that started in 2019, is the only observational one, and was the 8th registered.

Hypereosinophilic Syndrome

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

Browse Hypereosinophilic Syndrome studies →

Open to participants now

2 of the 10 studies in Hypereosinophilic Syndrome with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 7 Hypereosinophilic Syndrome studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hypereosinophilic Syndrome with a site in France, or all of them as a file.
02

Study summary

Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.

Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)

Read the detailed description

There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles:

A. a single flare-up of their disease, with favourable evolution spontaneously or under corticosteroid therapy, without further recurrence B. recurrent flare-ups with a variable free interval of several months to several years, with or without persistent eosinophilia between flare-ups C. a chronic disease requiring the continuation of a substantive treatment D. chronic asymptomatic HE for years: the mechanisms involved in the occurrence of possible organ damage are unknown

The primary objective of the study is to describe the frequency of the different clinical manifestations during the diagnostic and follow-up of the hypereosinophilic syndrome (HES). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to eosinophilia.

03

Conditions studied

  • Eosinophilia
  • Hypereosinophilic Syndrome

Browse trials for

Keywords

  • Eosinophilia
  • Hypereosinophilia
  • Hypereosinophilic Syndrome
04

In context

Hypereosinophilic Syndrome Reclassified

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

Browse Hypereosinophilic Syndrome studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Compared within Hypereosinophilic Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Eosinophilia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Hypereosinophilia and Hypereosinophilic Syndromes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or Women of any age :
  • With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)
  • With an AEC > 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)
  • HES diagnosis since 2005/01/01
  • Patients socially insured
  • Patient who agreed to participate to the study, its proceedings and duration.

Exclusion criteria

Exclusion Criteria:

  • Known infection
  • Not socially insured
  • Person unable to receive a enlighten information
  • Person who refuse to sign the consent
  • Persons deprived of their liberty
  • Persons benefiting from a system of legal protection (tutelage / guardianship)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Eosinophilia/Hypereosinophilic syndrome

    patient with eosinophilia and/or hypereosinophilic syndrome

    Biological: Biological sample

Interventions

  • BiologicalBiological sample

    Additional blood samples for biobanking

07

What researchers measure

Primary outcomes

  1. Frequency of the different clinical manifestations at time of diagnosis and during follow-up of the hypereosinophilic syndrome (HES)

    The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia.

    Time frame: 10 years

Secondary outcomes

  1. Frequency of the evolutionary profiles

    Frequency of the different evolutionary profiles.

    Time frame: 10 years

  2. Frequency of complications depending of the type of HES

    Frequency of complications (organ damages) depending on the type of HES (idiopathic, reactive, clonal…).

    Time frame: 10 years

  3. Frequency of organ damage profiles before and after 18 years old.

    Describe the characteristics of pediatrics HE/HES vs adult HE/HES.

    Time frame: 10 years

  4. Frequency of clinical complications profiles before and after 18 years old.

    Clinical characteristics of pediatrics HE/HES vs adult HE/HES.

    Time frame: 10 years

  5. Frequency of HLA alleles and variants / mutations on other genes of HE/HES

    Predisposing factors in HE/HES by various genomic approaches

    Time frame: 10 years

  6. Serum biomarkers

    to explore Potential predisposing factors in HE/HES: serum markers predictive of interest in eosinophilopoiesis (IL5), tissue homing (eotaxins, etc.)

    Time frame: 10 years

  7. Difference in Membrane activation markers of HE patients (asymptomatic) versus SHE (symptomatic).

    Predisposing factors in HE/HES by various genomic approaches

    Time frame: 10 years

  8. Difference in Eosinophilic gene expression profiles of HE patients (asymptomatic) versus SHE (symptomatic).

    Predisposing factors in HE/HES by various genomic approaches

    Time frame: 10 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Lefevre G, Bleuse S, Puyade M, Moulis G, Neel A, Abisror N, Baudet A, Bonnotte B, Dion J, Dossier A, Grall M, Lifermann F, Limal N, Lioger B, Machelart I, Mohr C, Outh R, Queyrel-Moranne V, Slama B, Trefond L, Abou Chahla W, Ackerman F, Belfeki N, Berezne A, Blade JS, Bouderbala MA, Chebrek S, Cottin V, De Almeida S, De Masson A, Dezoteux F, Goulenok T, Jachiet V, Jouvray M, Latu I, Ledoult E, Leurs A, Lugosi M, Martin M, Melboucy-Belkhir S, Morati-Hafsaoui C, Quemeneur T, Rohmer J, Roy-Peaud F, Sanges S, Schleinitz N, Staumont-Salle D, Taille C, Terriou L, Tieulie N, Koenga JDE, Schwarb L, Panel K, Kahn JE, Groh M; COHESion study group. Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort. Allergy. 2025 Apr;80(4):1100-1110. doi: 10.1111/all.16463. Epub 2025 Jan 5. PubMed 39757773 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2019 (actual). Primary completion is estimated for May 2029, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
Jul 12, 2019
StartActual
May 6, 2019
Primary completionEst.
May 6, 2029
CompletionEst.
May 2031
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04018118
Responsible party
Sponsor
First posted
Jul 12, 2019
Start date
May 6, 2019
Primary completion
May 6, 2029 (estimated)
Completion
May 2031 (estimated)
Last update
Feb 20, 2026

Study contacts

Guillaume Lefevre, MD
Contact
Guillaume.lefevre@chru-lille.fr
03 20 44 55 72 ext. +33
Guillaume Lefevre
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion